Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TP53 double hit predicts aggressive myeloma

Key clinical point: Relapsed multiple myeloma becomes increasingly aggressive and difficult to treat with additional TP53 alterations.

Major finding: Starting from a 1:3 coculture of biallelic and monoallelic TP53 inactivated clones, it took 35 days for the biallelic clones to dominate the cell culture.

Study details: A cell line study evaluating TP53 mutations in multiple myeloma.

Disclosures: The study was funded by Deutsche Forschungsgemeinschaft, the CDW Stiftung, and the IZKF Würzburg. The investigators reported additional support from the CRIS foundation, the German Cancer Aid, and the University of Würzburg.

Citation:

Munawar U et al. Blood. 2019 Jul 24. doi: 10.1182/blood.2019000080.